Thirzepatide - how does it work?
Peptide incretin receptor agonists
The following compounds are advanced modulators of metabolic pathways studied in the context of their effects on receptors GLP-1, GIP i glucagon. Research highlights differences in potency, receptor selectivity and metabolic response dynamics.
1. thirzepatide
The most important effects observed in the study
- strong activation of GLP-1 and GIP receptors, which translates into a pronounced synergistic effect, according to the study,
- pronounced effect on appetite and satiety regulation,
- Significant improvement in glucose parameters in experimental models,
- Beneficial effects on lipid metabolism.
How does it work?
Thiogastatide is a dual agonist (dual-targeted peptide). Publications have shown that simultaneous activation of GLP-1 and GIP enhances signals responsible for regulating energy metabolism more than selective GLP-1 agonists. Studies have also shown that its action improves metabolic sensitivity and reduces energy intake in animal and cellular models.
2. retatrutide
The most important effects observed in the study
- simultaneous activation of as many as three receptors: GLP-1, GIP and glucagon,
- stronger metabolic effect than dual-activation compounds,
- Increased energy burn and higher thermogenic effect in experimental models,
- Effect on improving lipid profile.
How does it work?
Retatrutide is a so-called triple agonist, or tri-receptor modulator. In preclinical and early clinical studies, activation of the glucagon receptor has been shown to increase energy expenditure, and combining this with GLP-1 and GIP results in the most potent metabolic effect among incretin analogs known to date. Scientific studies highlight its prolonged duration of activity and high potency.
3. semaglutide
The most important effects observed in the study
- Highly selective GLP-1 receptor activation,
- Significantly reduced appetite and increased satiety in experimental models,
- Improving glycemic control,
- Very long duration of action due to the stability of the molecule.
How does it work?
Semaglutide is a classical, potent GLP-1 agonist with prolonged activity. In research studies, it shows a consistent, predictable action profile due to structural modifications that increase its binding to albumin. It is widely used as a reference ("gold standard") for comparative studies with newer multi-receptor agonists.
4. orforglipron
The most important effects observed in the study
- Strong agonist activation of GLP-1 while maintaining the small-molecule (non-peptide) form,
- greater bioavailability compared to classical peptides,
- Potentially faster dynamics of action,
- Modulation of satiety and postprandial metabolic parameters.
How does it work?
Orforglipron (formerly LY3502970) is one of the first non-peptide GLP-1 agonists. Unlike typical peptides, it is a stable small molecule, which gives it a unique pharmacokinetic profile. Studies show effects similar to classic GLP-1 agonists, but with different pharmacodynamics, making it an interesting tool for new research models.
Comparison based on scientific sources
| Substance | Mechanism | The strongest action (according to studies) | Key feature |
|---|---|---|---|
| Tirzepatide | GLP-1 + GIP | Strong satiety effect and reduction of energy intake | Synergistic dual activation |
| Retatrutide | GLP-1 + GIP + Glucagon | Highest energy consumption, strong metabolic impact | Triple agonist - widest receptor profile |
| Semaglutide | GLP-1 | Stable, predictable metabolic effect | Single activation |
| Orforglipron | GLP-1 (non-peptide) | High bioavailability and different pharmacokinetics | Small molecule - unique mechanism of action |
GLP/GIp/Glucagon what effects does it have?
Latest research confirm that a new formulation, approved by the U.S. Food and Drug Administration (FDA), can significantly help people who are overweight or obese. With regular intake of this peptide, healthy individuals have the potential to reduce up to a quarter of their initial body weight. Significantly, these effects are comparable to those obtained through bariatric surgery, while the therapy did not require drastic changes in patients' daily lifestyles. Of course, better eating habits and physical activity can further enhance the results.
In a large study involving 2,500 people without type 1 diabetes, researchers observed spectacular results. More than 60% participants, who took doses of 5 to 15 mg for more than a year, managed to reduce their body weight by a minimum of 20%. In some patients, the weight loss was even 22.5-25%, which in practice meant a weight loss of about 28 kilograms. Results these show that the formulation can be an attractive option for people who care about their figure and health.
Thiopeptide is a cutting-edge drug that is changing the approach to treating type 2 diabetes and overweight. This innovative peptide acts on the body in a complex way, activating two key gut hormones - GLP-1 and GIP - responsible for both blood glucose regulation and appetite control.
Thanks to its unique chemical structure, tirzepatyd induces a quick sense of satiety after a meal, while stabilizing blood sugar levels. This makes both maintaining normal glucose levels and reducing weight easier, making it a valuable tool in weight loss therapy.
Previous studies indicate that tirzepatyd is superior to classical treatments in terms of efficacy, and is convenient to use. It is particularly helpful for people who are overweight or obese. Administered once a week, it acts on GLP-1 and GIP receptors, leading to a reduction in appetite, accelerated metabolism and gradual weight loss.
The secret of tirzepatydu lies in its ability to mimic the natural gut hormones released after eating. It slows gastric emptying and amplifies satiety signals sent to the hypothalamus, which helps effectively reduce the amount of food consumed.
Thirzepatide brings a new quality to the treatment of diabetes and weight problems, offering patients more effective and convenient solutions. It enables better control of sugar levels, curbing appetite and achieving a healthier body weight.
Source:
The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials
